Contrast agent with MRI improves detection of lymph nodes metastases

Feb 01, 2010

Addition of the contrast agent gadolinium during magnetic resonance imaging (MRI) for primary tumor assessment improved accuracy for detecting lymph node metastases, according to a new study published online February 1 in the Journal of the National Cancer Institute. Gadolinium-enhanced MRI is primarily used to visualize primary tumors, highlight tumor vascularity, and increasingly to detect and evaluate lymph node metastases. In light of this systematic review, the authors recommend that contrast highlighting be included as a malignancy criterion when this agent is used for primary tumor visualization.

Wenche M. Klerkx, M.D., Ph.D., Department of Gynecology and Obstetrics, University Medical Centre Utrecht, the Netherlands, and colleagues searched the literature for studies that compared the diagnostic accuracy of gadolinium-enhanced MRI for staging lymph node with that of histopathologic examination. The researchers conducted a meta-analysis that encompassed more than 30 studies from the last 10 years and reported summary sensitivity and specificity of MRI for detecting nodal metastases.

The researchers found that overall accuracy of gadolinium-enhanced MRI for the detection of nodal metastases was moderate. They also concluded that incorporating contrast enhancement in the malignancy criteria improves the accuracy of this diagnostic test.

"We further advocate the use of uniform malignancy criteria, including contrast enhancement, for standardization of future evaluations," the authors write. "Gadolinium enhancement by itself does not have the diagnostic accuracy to replace histopathologic examination of lymph nodes; however, it can help identify suspicious that should be surgically collected for histopathologic examination."

Study limitations: Not all of the included studies reported diagnostic study quality, which precluded formal analyses based on the quality assessment items. A regression test for small-study effects was statistically significant, indicating that the retrieved studies had results that may not be representative of the full range of evidence that has been produced (publication bias). In the overall analyses of the diagnostic accuracy of gadolinium-enhanced magnetic resonance imaging for the detection of lymph node metastases, studies were pooled without regard to the primary tumor site.

Explore further: Target growth-driving cells within tumors, not fastest-proliferating cells

add to favorites email to friend print save as pdf

Related Stories

FDA wants MRI contrast agent warning

May 23, 2007

The U.S. Food and Drug Administration wants a warning printed on the labels of all gadolinium-based magnetic resonance imaging contrast agents.

Biomarker predicts disease recurrence in colorectal cancer

Feb 17, 2009

Findings published in the Journal of the American Medical Association by researchers at Thomas Jefferson University show that the presence of a biomarker in regional lymph nodes is an independent predictor of disease recurr ...

New blood marker may predict prostate cancer spread

Feb 27, 2008

Researchers report finding a new blood biomarker that enables close to 98 percent accuracy in predicting the spread of prostate cancer to regional lymph nodes. Their study is published in the March 1 issue of Clinical Ca ...

Better Insight into Brain Anatomical Structures

May 29, 2007

Magnetic resonance imaging is a very effective method for revealing anatomical details of soft tissues. Contrast agents can help to make these images even clearer and allow physiological processes to be followed in real time. ...

Better insight into brain anatomical structures

Jun 15, 2007

Magnetic resonance imaging is a very effective method for revealing anatomical details of soft tissues. Contrast agents can help to make these images even clearer and allow physiological processes to be followed in real time. ...

Recommended for you

Same cancer, different time zone

21 hours ago

Just as no two people possess the same genetic makeup, a recent study has shown that no two single tumor cells in breast cancer patients have an identical genome.

User comments : 0